
Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy with high recurrence rates and poor prognosis. Treatment remains a clinical challenge due to the tumor’s "immune cold" phenotype, which exhibits profound mechanisms of immune evasion that obstruct both conventional therapies and modern checkpoint immunotherapies. Histologically, ACC tumors are biphasic, composed of distinct luminal epithelial and abluminal myoepithelial cell populations
This research set out to answer how these two different cell populations cooperate to create a barrier against the immune system, and how their distinct characteristics shape the overall tumor environment to drive cancer progression.
By mapping the tumor ecosystem at a single-cell resolution, we uncovered a striking division of labor between the two cell types. We discovered that antigen-presentation and tolerance-induction pathways are highly activated in luminal cells, while pathways related to the downregulation of antigen presentation are activated in myoepithelial cells. Next, we characterized the direct cancer-immune cell interactions. We found that luminal cells actively paralyze traveling immune cells using specific surface signals to induce a state of permanent dysfunction. Conversely, myoepithelial cells focus on physical defense, altering the surrounding structural scaffolding to trap immune cells and prevent them from reaching the tumor core.
We conclude that ACC successfully evades the immune system through a dual-defense strategy: luminal cells drive active immunological tolerance, while myoepithelial cells construct a molecular and physical shield. Overcoming this disease will require novel therapies that simultaneously target both molecular axes.